Seattle biotech Omeros selling drug franchise in deal valued at over $1B
Omeros, a Seattle-based biotech company, has announced it is selling its Omidria franchise to Rayner Surgical Group. Omidria helps to prevent excessive pupil constriction in cataract surgery.
“We are immensely proud of our Omidria team and its achievements over the last seven years. We believe that Rayner, with its expertise and increasingly strong international presence in ophthalmology, represents a great home for Omidria and the product’s commercial team,” said Gregory Demopulos, CEO of Omeros.